



喜诺
Genobio



FungiXpert[®]

Aspergillus Galactomannan Detection Kit (CLIA)

Product code: FAGM012-CLIA

Obtain result in 60min



Overview

The incidence of Invasive Aspergillosis (IA) in immunosuppressed patients is rapidly increasing due to antibiotic abuse. *Aspergillus fumigatus* is one of the most common pathogens that cause severe aspergillus infection in patients with immunosuppressive disease, followed by *Aspergillus flavus*, *Aspergillus niger* and *Aspergillus terreus*. Due to lack of typical clinical manifestations and effective early diagnosis methods, IA has a high mortality rate of 60% to 100%.

FungiXpert® Aspergillus Galactomannan Detection Kit (CLIA) is the **world's first and only** quantitative reagent for the early detection of invasive Aspergillus infection with **chemiluminescence integrated reagent strip**. It is fully automated with FACIS to complete sample pretreatment and experimental testing, fully liberating the hands of laboratory physician and greatly improve detection accuracy.

Product Characteristics

Basic Parameters	Aspergillus Galactomannan Detection Kit (CLIA)
Method	Chemiluminescence immunoassay
Sample Type	Serum, BAL fluid
Specification	12 Tests/kit
Applicable instrument	Full-Automatic Chemiluminescence immunoassay System (FACIS)
Detection Time	40 min
Detection Objects	<i>Aspergillus spp.</i>
Stability	The kit is stable for 1 years at 2°C-8°C
Low detection limit	0.1 µg/L


Applicable Department

- Respiration department
- Cancer department
- Transplantation department
- Hematology department
- ICU
- Infectious department


Product Advantages




Saving time is saving life! Obtain result within 60 min.



All in one! Integrated reagents and consumables together, more convenient.



Unique sample pretreatment system using micron film with invention patent.




Fully automatically perform experiment process & data analysis.

Clinical Performance

- **Low detection limit**
Limit of Detection (LoD) is 0.1 µg/L
- **Sensitivity and specificity**

	Serum (Adult)	Serum (Pediatrics)	BAL (Adult)
Sensitivity	92.7%	94.3%	94.6%
Specificity	95.1%	94.7%	95.9%

- **Support the diagnosis of invasive aspergillosis in early stage (Pazos et al., 2005)**
GM is 5-8 days earlier than the clinical symptoms of invasive aspergillosis (IA);
GM is 7.2 days earlier than high-resolution CT scans;
GM is on average 12.5 days earlier than starting empirical antifungal treatment.
- **Monitor disease progression and therapeutic response, and predict outcome (Pazos et al., 2005)**



- **Recommendations**
Recommended by IDSA guideline for Aspergillosis 2016 (Patterson et al., 2016) and ESCMID-ECMM-ERS guideline for Aspergillosis 2018 (Ullmann et al., 2017)



Innovation for Better Health

Tel: +86(22)60978609 ext. 8605/8606/8608/8609

Fax: +86(22)60978609-804

E-mail: marketing@era-bio.com / customer@era-bio.com

Web: www.era-bio.com



 **Genobio Pharmaceutical Co., Ltd.**

Add: 2-1,2,3-101, No.2 Zone, Binlv Industrial Park, Binhai
Tourism Area, Binhai New Area, Tianjin 300480, P. R. China

 **Tianjin Era Biology Technology Co., Ltd.**

Add: 1601, Building C2, TEDA MSD-C, No. 79, 1st Avenue, Tianjin
Economic-Technological Development Area, Tianjin 300457,
P. R. China

Genobio is wholly-owned subsidiary of Era Biology Group